|
|
| | BIIB129 Basic information |
| Product Name: | BIIB129 | | Synonyms: | BIIB129;N-Methyl-N-(cis-3-methyl-3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide;2-Propenamide, N-methyl-N-[cis-3-methyl-3-[[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy]cyclobutyl]- | | CAS: | 2770960-52-4 | | MF: | C19H22N6O2 | | MW: | 366.42 | | EINECS: | | | Product Categories: | | | Mol File: | 2770960-52-4.mol |  |
| | BIIB129 Chemical Properties |
| density | 1.325±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 0.774±0.10(predicted) | | form | Solid | | color | White to off-white |
| | BIIB129 Usage And Synthesis |
| Uses | BIIB129 is a covalent, selective, small molecule inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of BTK by covalently binding to Cys481 in BTK, thereby affecting the function of B cells and myeloid cells. BIIB129 can be used in multiple sclerosis (MS) research[1]. | | References | [1] Himmelbauer M K, et al. Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis[J]. Journal of Medicinal Chemistry, 2024. DOI:10.1021/acs.jmedchem.4c00220 |
| | BIIB129 Preparation Products And Raw materials |
|